Free Trial
OTCMKTS:CVSI

CV Sciences (CVSI) Stock Price, News & Analysis

CV Sciences logo
$0.03 +0.00 (+1.37%)
As of 06/18/2025 03:56 PM Eastern

About CV Sciences Stock (OTCMKTS:CVSI)

Key Stats

Today's Range
$0.03
$0.03
50-Day Range
$0.02
$0.03
52-Week Range
$0.02
$0.06
Volume
96,854 shs
Average Volume
214,876 shs
Market Capitalization
$5.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

Receive CVSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CV Sciences and its competitors with MarketBeat's FREE daily newsletter.

CVSI Stock News Headlines

Q1 2025 CV Sciences Inc Earnings Call
An AI run of epic proportions is only getting started
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
Q4 2024 CV Sciences Inc Earnings Call
See More Headlines

CVSI Stock Analysis - Frequently Asked Questions

CV Sciences' stock was trading at $0.0338 at the start of the year. Since then, CVSI shares have decreased by 12.7% and is now trading at $0.0295.
View the best growth stocks for 2025 here
.

CV Sciences, Inc. (OTCMKTS:CVSI) issued its quarterly earnings results on Thursday, August, 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). The firm had revenue of $5.13 million for the quarter, compared to the consensus estimate of $5.12 million. CV Sciences had a negative net margin of 12.25% and a negative trailing twelve-month return on equity of 89.43%.

Shares of CVSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CV Sciences investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Charlotte's Web (CWBHF), Cronos Group (CRON), Kushco (KSHB), NVIDIA (NVDA) and Organigram Global (OGI).

Company Calendar

Last Earnings
8/12/2021
Today
6/19/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:CVSI
Previous Symbol
NASDAQ:CVSI
Employees
70
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$2.39 million
Pretax Margin
-12.29%

Debt

Sales & Book Value

Annual Sales
$15.70 million
Price / Cash Flow
N/A
Book Value
$0.01 per share
Price / Book
2.95

Miscellaneous

Free Float
177,772,000
Market Cap
$5.45 million
Optionable
Not Optionable
Beta
0.47

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (OTCMKTS:CVSI) was last updated on 6/20/2025 by MarketBeat.com Staff
From Our Partners